Victory Capital Management Inc. Sells 5,599 Shares of Zoetis Inc. (NYSE:ZTS)

Victory Capital Management Inc. lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 382,044 shares of the company’s stock after selling 5,599 shares during the period. Victory Capital Management Inc. owned 0.08% of Zoetis worth $75,404,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of ZTS. Blue Bell Private Wealth Management LLC grew its position in shares of Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after buying an additional 89 shares during the last quarter. Independence Bank of Kentucky grew its holdings in Zoetis by 371.4% in the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after purchasing an additional 130 shares during the last quarter. Ramirez Asset Management Inc. acquired a new position in shares of Zoetis during the third quarter worth $35,000. First Financial Corp IN lifted its holdings in shares of Zoetis by 57.2% during the 4th quarter. First Financial Corp IN now owns 217 shares of the company’s stock valued at $43,000 after purchasing an additional 79 shares during the last quarter. Finally, FinTrust Capital Advisors LLC lifted its holdings in shares of Zoetis by 42.1% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 260 shares of the company’s stock valued at $45,000 after purchasing an additional 77 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 363 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $197.74, for a total value of $71,779.62. Following the completion of the transaction, the executive vice president now directly owns 20,417 shares in the company, valued at approximately $4,037,257.58. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders sold 2,209 shares of company stock worth $371,293. 0.16% of the stock is owned by corporate insiders.

Zoetis Stock Down 0.1 %

ZTS stock opened at $167.07 on Friday. The company has a market capitalization of $76.41 billion, a P/E ratio of 32.19, a price-to-earnings-growth ratio of 2.62 and a beta of 0.86. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The firm’s fifty day simple moving average is $169.48 and its 200-day simple moving average is $178.89. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.34 by $0.04. The company had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.74%. The firm’s revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.31 earnings per share. As a group, equities research analysts forecast that Zoetis Inc. will post 5.78 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 1.03%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is 33.33%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ZTS. The Goldman Sachs Group upped their target price on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Stifel Nicolaus cut their price objective on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 price objective (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Barclays dropped their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 23rd. Finally, StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $216.13.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.